Navigation Links
Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
Date:9/19/2007

WIXOM, Mich., Sept. 19 /PRNewswire-FirstCall/ -- Rockwell Medical Technologies, Inc. (Nasdaq: RMTI), a leading, innovative manufacturer and developer of concentrates and specialty pharmaceuticals focused on the end- stage-renal-disease market (ESRD), announced today that it has commenced enrollment in its Phase IIb dose-ranging study for Soluble Ferric Pyrophosphate (SFP), a physiological iron-maintenance therapy drug.

The Phase IIb dose-ranging study is a nine-month, controlled multi-center, double-blind study consisting of up to 130 patients at multiple dialysis centers in the United States. Patients will receive SFP during their normal three times/week dialysis regimen. The primary objectives of this study are to evaluate both safety and efficacy of SFP at varying dosage levels and to determine the optimal concentration of SFP that will maintain iron balance within the target hemoglobin range, in patients undergoing hemodialysis. Secondary endpoints include evaluating efficacy for changes in hemoglobin levels over time, reticulocyte hemoglobin content, incidence of systemic infection episodes and to quantify the amount of SFP iron transferred from the dialysate directly to the blood during the dialysis session. Results of this Phase IIb study are expected by the end of 2008.

Robert L. Chioini, Chairman and CEO of Rockwell stated, "We are excited to initiate this important step in our clinical development plan for SFP, a key product in Rockwell's renal drug development pipeline. The completion of this study will enable us to initiate our planned Phase III pivotal study program for FDA market approval of SFP. Mr. Chioini also stated, "We have assembled a team of top-tier investigators who will be conducti
'/>"/>

SOURCE Rockwell Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
9. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015 First Choice Wellness Care ... Astanza Duality and is the only clinic in the ... tattoo removal treatments. The practice has recently expanded their ... brand to showcase their focus in the procedure. They ... results, faster ink clearance, and superior service. ...
(Date:6/30/2015)... Kalifornien, und KOPENHAGEN, Dänemark, 30. Juni 2015 ... ein Weltmarktführer der klinischen und kommerziellen Produktion ... gab heute bekannt, dass das Unternehmen im ... Ausbau der nordamerikanischen Produktionsanlage in ... einer Einweg-Anlage Bioreactor 6Pack™ komplettiert hat. Die ...
(Date:6/30/2015)... , June 30, 2015  Marken, the leading clinical ... life sciences industry, has been granted permission by the ... of clinical drug product in Korea.  This precedent-setting shipment ... to continue receiving their clinical trial drugs ... The emergency was caused by recent partial ...
Breaking Medicine Technology:First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3Marken Delivers Direct To Patients During MERS Outbreak 2Marken Delivers Direct To Patients During MERS Outbreak 3
... SAN FRANCISCO, May 6 Medizone (Pink Sheets: ... the first in a series of trials designed ... System can rapidly eliminate hospital-based bacterial pathogens known ... deaths and serious infections currently plaguing the healthcare ...
... BioTechnologies, Inc. (TriLink), a leading provider of custom ... Start PCR reagent - CleanAmp(TM) dNTPs.CleanAmp(TM) dNTPs offer ... PCR results. Using CleanAmp(TM) dNTPs allows precise ... by blocking DNA polymerase nucleotide incorporation until heat ...
Cached Medicine Technology:Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun 2
(Date:6/30/2015)... , ... June 30, 2015 , ... The American Lung ... at a media event in San Diego. Speakers and clean air advocates included San ... medicine, Natalie Germuska of Kindred Hospital, and Daniel Sullivan, founder and president of Sullivan ...
(Date:6/30/2015)... ... June 30, 2015 , ... According to a June 15th ... grant to study how sensory stimuli can be used to “decrease children’s anxiety and ... for children with autism, will compare patient experience in a “typical dental environment” with ...
(Date:6/30/2015)... NY (PRWEB) , ... June 30, 2015 , ... ... when buying eyeglasses online , finally its here, http://www.express-glasses.com ... express shipping rates, for many location, ask about shipping with DHL Express when ...
(Date:6/30/2015)... ... June 30, 2015 , ... Rocky Mountain Oils, a leading non-MLM supplier ... added a new CEO, Mr. Darold Francis. The changes will help enhance the company’s ... that customers have come to know and respect for over eight years. , “I ...
(Date:6/30/2015)... ... June 30, 2015 , ... MJH Associates today ... Healthcare Research & Analytics , a consultative healthcare market research practice that is ... businesses. HRA offers quantitative and qualitative, custom and multi-client primary market research services ...
Breaking Medicine News(10 mins):Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 2Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 3Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3
... public, even families are involved, study finds , FRIDAY, ... family history of an incurable genetic disease isn,t worry ... report being discriminated against by insurance companies, relatives and ... Yvonne Bombard and colleagues at the University of British ...
... Children,s Hospital, Summit County ... to provide full-range of services to families with children who have ... Copley Township , , FAIRLAWN, Ohio, ... creation of the Robert J. Keegan Family Center for Autism. , , ...
... Denmark, Friday 12 June 2009: First line treatment with ... ,good, clinical response (ACRp90) in patients newly diagnosed with ... deficient IL-18 response of natural killer (NK) cells*, according ... a joint congress with the 2009 Congress of the ...
... June 2009: Three new studies have individually shown the ... with a good safety profile, in children under four ... associated with improved Health-Related Quality of Life (HRQoL) in ... are being presented at the Paediatric Rheumatology European Society ...
... Denmark, Friday 12 June 2009: Over half (56%) of ... chronic inflammatory disease of the gum and surrounding ligaments ... fewer teeth than healthy matched controls, high prevalence of ... (the extent of periodontal support that has been destroyed ...
... frailty stand to benefit from the first potential ... study presented today by Penn Medicine researchers at ... Ghrelin, a hormone that stimulates appetite, was administered ... geriatric syndrome characterized by unintentional weight loss, weakness, ...
Cached Medicine News:Health News:People With Huntington's Report Discrimination 2Health News:People With Huntington's Report Discrimination 3Health News:Autism Family Foundation Introduces The Robert J. Keegan Family Center for Autism 2Health News:Autism Family Foundation Introduces The Robert J. Keegan Family Center for Autism 3Health News:Early treatment of systemic onset JIA with anakinra restores the IL-18 response 2Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 2Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 3Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 4Health News:Over half of people with rheumatoid arthritis have periodontitis 2Health News:Over half of people with rheumatoid arthritis have periodontitis 3Health News:Appetite-stimulating hormone is first potential medical treatment for frailty in older women 2
... The MicroAire® Hi Speed Pulse Lavage ... bone surfaces as well as cleansing ... Now a great system just got ... effective with the addition of ...
... Staple is a novel shape memory alloy bone ... of its Nitinol construction, the prongs of the ... upon application of a heating current. This results ... response of bone and cause adjustable compression across ...
... deformity of the ankle joint with ... fusion of the ankle joint, fractures ... where reconstruction is impossible, and fracture/dislocations ... severe arthritic changes and loss of ...
The Buechel-pappas™ Total Ankle Replacement is a time-tested system which is the result of more than twenty years of development, clinical investigation, and use. The components have been avai...
Medicine Products: